Researchers are excited about this new drug, a groundbreaking dual agonist showing significant data in clinical trials for body loss . It acts by targeting both hormones : GLP-1 and GIP, which , when engaged , help influence cravings and enhance energy expenditure . Preliminary observations suggest considerable weight reduction and likely benefits